These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 31343289)

  • 1. Patient profile with ATTR-FAP and evaluation of the safety and efficacy of tafamidis meglumine in Japan - interim analysis in post-marketing surveillance.
    Ishii T; Sekijima Y; Ando Y
    Amyloid; 2019; 26(sup1):45-46. PubMed ID: 31343289
    [No Abstract]   [Full Text] [Related]  

  • 2. Quality of life assessment after 6 months of initiating treatment with tafamidis in patients with non-Val30Met mutations.
    Cárdenas-Soto K; Torres-Octavo B; Mendoza-Tejeda C; Fueyo-Rodríguez O; Domínguez-Rico C; Gonzalez-Duarte A
    Amyloid; 2019; 26(sup1):57-58. PubMed ID: 31343329
    [No Abstract]   [Full Text] [Related]  

  • 3. Significant reduction in proteinuria after treatment with tafamidis.
    Ferrer-Nadal A; Ripoll T; Uson M; Figuerola A; Andreu H; Losada I; Gonzalez J; Cisneros-Barroso E; Buades J
    Amyloid; 2019; 26(sup1):67-68. PubMed ID: 31343359
    [No Abstract]   [Full Text] [Related]  

  • 4. Characteristics of Patients with Hereditary Transthyretin Amyloidosis and an Evaluation of the Safety of Tafamidis Meglumine in Japan: An Interim Analysis of an All-case Postmarketing Surveillance.
    Ishii T; Hirano Y; Matsumoto N; Takata A; Sekijima Y; Ueda M; Ando Y
    Clin Ther; 2020 Sep; 42(9):1728-1737.e6. PubMed ID: 32800381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of tafamidis treatment on transthyretin (TTR) stabilization, efficacy, and safety in Japanese patients with familial amyloid polyneuropathy (TTR-FAP) with Val30Met and non-Val30Met: A phase III, open-label study.
    Ando Y; Sekijima Y; Obayashi K; Yamashita T; Ueda M; Misumi Y; Morita H; Machii K; Ohta M; Takata A; Ikeda S
    J Neurol Sci; 2016 Mar; 362():266-71. PubMed ID: 26944161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comprehensive safety profile of tafamidis in patients with transthyretin amyloid polyneuropathy.
    Huber P; Flynn A; Sultan MB; Li H; Rill D; Ebede B; Gundapaneni B; Schwartz JH
    Amyloid; 2019 Dec; 26(4):203-209. PubMed ID: 31353964
    [No Abstract]   [Full Text] [Related]  

  • 7. Tafamidis (Vyndaqel): a light for FAP patients.
    Nencetti S; Rossello A; Orlandini E
    ChemMedChem; 2013 Oct; 8(10):1617-9. PubMed ID: 24000164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tafamidis: A Review in Transthyretin Amyloidosis with Polyneuropathy.
    Lamb YN; Deeks ED
    Drugs; 2019 Jun; 79(8):863-874. PubMed ID: 31098895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transthyretin (ATTR) amyloidosis nephropathy: lessons from a TTR stabilizer molecule.
    Rocha A; Silva A; Cardoso M; Beirão I; Alves C; Teles P; Coelho T; Lobato L
    Amyloid; 2017 Mar; 24(sup1):81-82. PubMed ID: 28434370
    [No Abstract]   [Full Text] [Related]  

  • 10. Tafamidis for transthyretin amyloidosis.
    de Lartigue J
    Drugs Today (Barc); 2012 May; 48(5):331-7. PubMed ID: 22645721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is it better than it seems or just good enough? The tafamidis saga.
    de Carvalho M
    Muscle Nerve; 2012 Dec; 46(6):839-40. PubMed ID: 23042137
    [No Abstract]   [Full Text] [Related]  

  • 12. Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes.
    Maurer MS; Grogan DR; Judge DP; Mundayat R; Packman J; Lombardo I; Quyyumi AA; Aarts J; Falk RH
    Circ Heart Fail; 2015 May; 8(3):519-26. PubMed ID: 25872787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area.
    Cortese A; Vita G; Luigetti M; Russo M; Bisogni G; Sabatelli M; Manganelli F; Santoro L; Cavallaro T; Fabrizi GM; Schenone A; Grandis M; Gemelli C; Mauro A; Pradotto LG; Gentile L; Stancanelli C; Lozza A; Perlini S; Piscosquito G; Calabrese D; Mazzeo A; Obici L; Pareyson D
    J Neurol; 2016 May; 263(5):916-924. PubMed ID: 26984605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Bioequivalence of Tafamidis 61-mg Free Acid Capsules and Tafamidis Meglumine 4 × 20-mg Capsules in Healthy Volunteers.
    Lockwood PA; Le VH; O'Gorman MT; Patterson TA; Sultan MB; Tankisheva E; Wang Q; Riley S
    Clin Pharmacol Drug Dev; 2020 Oct; 9(7):849-854. PubMed ID: 32196976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tafamidis dramatically improved severe proteinuria in a patient with TTR V30M hereditary ATTR amyloidosis.
    Ikeda SI; Hineno A; Ichikawa T; Makino M
    Amyloid; 2019 Jun; 26(2):99-100. PubMed ID: 31090446
    [No Abstract]   [Full Text] [Related]  

  • 16. Causes of Cardiovascular Hospitalization and Death in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial [ATTR-ACT]).
    Miller AB; Januzzi JL; O'Neill BJ; Gundapaneni B; Patterson TA; Sultan MB; López-Sendón J
    Am J Cardiol; 2021 Jun; 148():146-150. PubMed ID: 33667442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathologic and genetic features of early- and late-onset FAP type I (FAP ATTR Val30Met) in Japan.
    Sobue G; Koike H; Misu K; Hattori N; Yamamoto M; Ikeda S; Ando Y; Nakazato M; Inukai A
    Amyloid; 2003 Aug; 10 Suppl 1():32-8. PubMed ID: 14640040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Failure of Tafamidis to Halt Progression of Ala36Pro TTR Oculomeningovascular Amyloidosis.
    Salvi F; Volpe R; Pastorelli F; Bianchi A; Vella A; Rapezzi C; Mascalchi M
    J Stroke Cerebrovasc Dis; 2018 Sep; 27(9):e212-e214. PubMed ID: 29779881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tafamidis for the Treatment of Hereditary Transthyretin Amyloid Cardiomyopathy: A Case Report.
    Fujita T; Inomata T; Kaida T; Iida Y; Ikeda Y; Nabeta T; Ishii S; Maekawa E; Naruke T; Koitabashi T; Kitamura E; Sekijima Y; Ako J
    Cardiology; 2017; 137(2):74-77. PubMed ID: 28152524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.
    Sekijima Y
    J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):1036-43. PubMed ID: 25604431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.